Financial Performance - Aethlon Medical reported a cash balance of approximately $9.1 million as of June 30, 2024[8]. - Consolidated operating expenses for the fiscal first quarter were approximately $2.6 million, a decrease of approximately $800,000 or 24% compared to $3.4 million in the same period of 2023[8]. - The decrease in operating expenses was primarily due to a $600,000 reduction in general and administrative expenses and a $300,000 reduction in professional fees[8]. - The net loss for the fiscal quarter ended June 30, 2024, decreased to approximately $2.6 million from approximately $3.3 million in the same quarter of 2023[10]. - Net loss for the fiscal year ended June 30, 2024, was $2,571,440, a reduction from a net loss of $3,282,179 for the same period in 2023, reflecting a 22% improvement[20]. - Total operating expenses decreased to $2,620,858 for the fiscal year ended June 30, 2024, down from $3,408,160 in 2023, marking a 23% reduction[20]. - Basic and diluted net loss per share improved to $(0.34) for the fiscal year ended June 30, 2024, compared to $(1.35) in 2023, showing a significant improvement[20]. - Professional fees decreased to $614,082 for the fiscal year ended June 30, 2024, down from $976,638 in 2023, a reduction of 37%[20]. - General and administrative expenses decreased to $751,974 for the fiscal year ended June 30, 2024, down from $1,308,283 in 2023, indicating a 43% decrease[20]. Assets and Liabilities - Total current assets increased to $9,550,437 as of June 30, 2024, up from $6,225,788 on March 31, 2024, representing a 53% increase[18]. - Total liabilities rose to $2,702,801 as of June 30, 2024, compared to $2,479,650 on March 31, 2024, indicating an increase of approximately 9%[18]. - Cash and cash equivalents increased to $9,072,379 as of June 30, 2024, up from $5,441,978 on March 31, 2024, representing a 67% increase[18]. - Total stockholders' equity rose to $8,712,616 as of June 30, 2024, compared to $5,766,332 on March 31, 2024, reflecting a 51% increase[18]. - The weighted average number of common shares outstanding increased to 7,457,888 for the fiscal year ended June 30, 2024, compared to 2,431,476 in 2023, indicating a significant increase in shares[20]. Clinical Trials and Research - Aethlon Medical received two ethics committee approvals for a clinical trial of the Hemopurifier® in patients with solid tumors, with patient enrollment expected to open in October 2024[1][6]. - The primary endpoint of the upcoming trial is safety, monitoring adverse events and lab test changes in treated patients[6]. - The Hemopurifier has shown potential to improve therapeutic response rates to anti-PD-1 antibodies by binding and removing extracellular vesicles from the bloodstream[5]. - Aethlon Medical is exploring the Hemopurifier's use for treating life-threatening viral infections, with ongoing trials for COVID-19 in India[7]. - The company anticipates submitting applications to additional ethics committees in Australia and India, with potential approvals expected in late 2024[6]. - Aethlon Medical aims to conduct site initiation visits and begin patient enrollment at additional sites by the end of 2024[6].

Received Two Australian Ethics Committee Approvals for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies; Expects to Open Patient Enrollment in October of 2024 Achieved Significant 24% Reduction in Fiscal First Quarter Operating Expenses Compared to the Same Period in 2023Conference Call to be Held Today at 4:30 p.m. ETSAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeuti ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology issues a snapshot on recent news and developments for the treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.Read the full article at Investorideas.comhttps://www.investorideas.com/News/2024 ...

Bellberry Human Research Ethics Committee Granted Full Ethics Approval to the Pindara Private Hospital for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 AntibodiesSAN DIEGO, Aug. 12, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on August 6, 2024, the Bellberry Human Resea ...

SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2024, at 4:15 p.m. ET on Wednesday, August 14, 2024.Management will host a conference call on Wednesday, August 14, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following managem ...

Aethlon Medical, Inc. (NASDAQ:AEMD) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR James Frakes - Interim CEO and CFO Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Good day and welcome to the Aethlon Medical Fiscal Year End of 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation there will be an opportunity to as ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR For the transition period from ________ to __________ COMMISSION FILE NUMBER 001-37487 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) NEVADA 13-36328 ...

Exhibit 99.1 Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 27, 2024 -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments. Company Updates Aethlon Medic ...

Conference Call to be Held Today at 4:30 p.m. ETSAN DIEGO, June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments. Company UpdatesAethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system de ...

SAN DIEGO, June 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year ended March 31, 2024, at 4:15 p.m. ET on Thursday, June 27, 2024.Management will host a conference call on Thursday, June 27, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal ...